ERLOTINIB HCL
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ADENOCARCINOMA OF PANCREAS·+2
CAMBER PHARMACE
Indication
Metastatic non-small cell lung cancer with EGFR exon 21 L858R substitution mutation
Metastatic non-small cell lung cancer with EGFR exon 21 L858R substitution mutation refers to advanced, stage IV epithelial malignancy of the respiratory tract that has disseminated beyond the primary pulmonary site and regional lymph nodes. Read more about Metastatic non-small cell lung cancer with EGFR exon 21 L858R substitution mutation
20 drugs 16 manufacturers
Drugs that treat it
Common Metastatic non-small cell lung cancer with EGFR exon 21 L858R substitution mutation therapies.
ERLOTINIB HCL
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ADENOCARCINOMA OF PANCREAS·+2
MYLAN INSTITUTI
GEFITINIB
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·METASTATIC NON-SMALL CELL LUNG CANCER WITH EGFR EXON 21 L858R SUBSTITUTION MUTATION·+1
INGENUS PHARMAC
ERLOTINIB HCL
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ADENOCARCINOMA OF PANCREAS·+2
AREVA PHARMACEU
ERLOTINIB HCL
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ADENOCARCINOMA OF PANCREAS·+2
ALEMBIC PHARMAC
ERLOTINIB HCL
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ADENOCARCINOMA OF PANCREAS·+2
SUN PHARMACEUTI
ERLOTINIB HCL
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ADENOCARCINOMA OF PANCREAS·+2
ZYDUS PHARMACEU
ERLOTINIB HCL
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ADENOCARCINOMA OF PANCREAS·+2
NOVADOZ PHARMAC
ERLOTINIB HCL
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ADENOCARCINOMA OF PANCREAS·+2
ARMAS PHARMACEU
Filter & compare in the drug finder →Opens the drug finder with Metastatic non-small cell lung cancer with EGFR exon 21 L858R substitution mutation preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMetastatic non-small cell lung cancer with EGFR exon 21 L858R substitution mutation refers to advanced, stage IV epithelial malignancy of the respiratory tract that has disseminated beyond the primary pulmonary site and regional lymph nodes.
Pathophysiologically, it is defined by a specific single-nucleotide missense mutation in exon 21 of the epidermal growth factor receptor gene, resulting in an arginine substitution for leucine at codon 858 within the tyrosine kinase domain.
This alteration locks the kinase in a constitutively active conformation, driving ligand-independent downstream pro-survival and proliferative signaling cascades such as MAPK and PI3K/Akt pathways.
Clinically, this oncogenic driver is most prevalent in pulmonary adenocarcinomas and occurs with higher frequency in females, non-smokers, and individuals of East Asian descent.
- fda.gov
Metastatic non-small cell lung cancer with EGFR exon 21 L858R substitution mutation refers to advanced, stage IV epithelial malignancy of the respiratory tract that has disseminated beyond the primary pulmonary site and regional lymph nodes
- patsnap.com
Metastatic non-small cell lung cancer with EGFR exon 21 L858R substitution mutation refers to advanced, stage IV epithelial malignancy of the respiratory tract that has disseminated beyond the primary pulmonary site and regional lymph nodes Pathophysiologically, it is defined by a specific single-nucleotide missense mutation in exon 21 of the epidermal growth factor receptor gene, resulting in an arginine substitution for leucine at codon 858 within the tyrosine kinase domain This alteration loc...
- nih.gov
Pathophysiologically, it is defined by a specific single-nucleotide missense mutation in exon 21 of the epidermal growth factor receptor gene, resulting in an arginine substitution for leucine at codon 858 within the tyrosine kinase domain Clinically, this oncogenic driver is most prevalent in pulmonary adenocarcinomas and occurs with higher frequency in females, non-smokers, and individuals of East Asian descent
- lcfamerica.org
Clinically, this oncogenic driver is most prevalent in pulmonary adenocarcinomas and occurs with higher frequency in females, non-smokers, and individuals of East Asian descent
- lung.org
Clinically, this oncogenic driver is most prevalent in pulmonary adenocarcinomas and occurs with higher frequency in females, non-smokers, and individuals of East Asian descent
Personalize your experience
Follow Metastatic non-small cell lung cancer with EGFR exon 21 L858R substitution mutation and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.